Cite this: Calcitonin (CT) and RET Proto-Oncogene Measurement - Medscape - Jan 01, 2003. Introduction; Detection of MTC by Measuring Serum Calcitonin (CT) ...

Mutations in the RET proto-oncogene are responsible for the development of medullary thyroid carcinoma, which occurs sporadically or as part of the inherited cancer syndrome, multiple endocrine ...

Nature Biotechnology - RET-oncogene-targeting drugs draw notice. ... The companies are focusing their development efforts on NSCLC patients with rare genetic alterations in the RET proto-oncogene.

Researchers conducted a population-based cohort study to estimate the prevalence of major thyroid cancer-associated syndromes.

A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor (GRM1) signaling, in advanced melanoma. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This ...

RET rearrangement a new oncogene and potential target in lung cancer Peer-Reviewed Publication. University of Colorado Anschutz Medical Campus. In results presented at ASCO 2013, a ...

In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: rearrangement of the ...

Study uncovers cryptic vulnerabilities in RET oncogene that could aid in anti-cancer drug design. Download PDF Copy; Reviewed. Reviewed by Emily Henderson, B.Sc. Jun 24 2022.

Proto-oncogene tyrosine-protein kinase receptor Ret is a widely expressed oncogene and chromosomal rearrangements involving RET lead to fusion genes and RET kinase activation, which occur in lung ...

Background: Familial medullary thyroid carcinoma (FMTC) is related to germ-line mutations in the RET proto-oncogene. The mutations concern mainly cystein residues in exons 10 and 11, whereas ...

Introduction Detection of MTC by Measuring Serum Calcitonin (CT) Detection of MTC by Measuring the RET Proto-oncogene References 1-200 References 201-495 ...